In the STEP 1 trial timeline, the average weight-loss curve continued to descend steadily through this window, with participants passing the 10% weight-loss threshold on their way toward the trial's peak
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH
Most people who take tirzepatide do not have serious problems, but dizziness should never be ignored
Patients often describe a slow but noticeable change over several weeks rather than an abrupt return of hunger